Affiliation:
1. Irvine Department of Urology University of California Irvine California USA
Abstract
AbstractBackgroundTestosterone plays an important role in collagen metabolism, transforming growth factor‐β1 expression, and wound healing, which are all critical factors in pathogenesis of Peyronie's disease. Some clinical studies have suggested an association between Peyronie's disease and hypogonadism.ObjectiveWe sought to investigate whether baseline total testosterone levels influence response to intralesional collagenase clostridium histolyticum in Peyronie's disease.MethodsA retrospective review of patients receiving collagenase clostridium histolyticum injections with available total testosterone levels within 1 year of initial injection was conducted at a single institution. Baseline demographics, hypogonadal status, total testosterone, number of collagenase clostridium histolyticum cycles, and pre‐ and post‐treatment degrees of curvature were collected. Hypogonadism was defined as total testosterone <300 ng/dL.Results and discussionThirty‐six men were included with mean age of 58.2 years (SD 10.4) and mean body mass index 26.8 (SD 3.2). The mean total testosterone was 459.2 ng/dL (SD 144.0), and four (11.1%) were hypogonadal. Mean pre‐treatment curvature was 47.6°, and mean post‐treatment curvature was 27.8°, with mean improvement of 19.9° (40.1%). Hypogonadal status was not significantly associated with more severe curvature, 46.4° among hypogonadal men as to 57.5° among eugonadal men (p = 0.32). On linear regression analysis, total testosterone did not significantly predict improvement in degrees (β = –0.02; R2 = 0.06; p = 0.14) or percent (β = 0.0; R2 = 0.05; p = 0.18). Improvement in neither degrees nor percent differed significantly by hypogonadal status (p = 0.41 and 0.82, respectively). The cycle number did significantly predict greater improvement in curvature on both univariate and multivariate analyses (β = 5.7; R2 = 0.34; p < 0.01).ConclusionNeither total testosterone nor hypogonadism is associated with a degree of improvement after collagenase clostridium histolyticum treatment.
Subject
Urology,Endocrinology,Reproductive Medicine,Endocrinology, Diabetes and Metabolism
Reference18 articles.
1. Role of collagenase clostridium histolyticum in Peyronie's disease;Peak TC;Biol Targets Ther,2015
2. Nonsurgical management of Peyronie’s disease
3. Peyronie’s Disease: AUA Guideline
4. Intralesional collagenase Clostridium histolyticum in the management of Peyronie’s disease: current best practice
5. Augmenting intralesional collagenase treatment with testosterone therapy provides greater self‐assessed improvement in penile curvature due to Peyronie's disease. Androg;Shlykova N;Clin Res Ther,2020